Paragon Care Limited (PXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Paragon Care Limited (PXS) has a cash flow conversion efficiency ratio of 0.031x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€7.58 Million ≈ $8.87 Million USD) by net assets (€242.34 Million ≈ $283.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Paragon Care Limited - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Paragon Care Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Paragon Care Limited (PXS) financial obligations for a breakdown of total debt and financial obligations.
Paragon Care Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Paragon Care Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GRAPHENE MANUFACT.GROUP
F:0GF
|
N/A |
|
Kangda International Environmental Company Limited
STU:27K
|
0.001x |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
-0.145x |
|
Etga Group Ltd
TA:ETGA
|
0.014x |
|
Detection Technology OY
HE:DETEC
|
0.019x |
|
Ecomate Holdings Bhd
KLSE:0239
|
-0.103x |
|
Merafe
JSE:MRF
|
-0.033x |
|
Ryvu Therapeutics SA
WAR:RVU
|
-0.522x |
Annual Cash Flow Conversion Efficiency for Paragon Care Limited (2014–2023)
The table below shows the annual cash flow conversion efficiency of Paragon Care Limited from 2014 to 2023. For the full company profile with market capitalisation and key ratios, see Paragon Care Limited (PXS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | €251.96 Million ≈ $294.56 Million |
€17.75 Million ≈ $20.75 Million |
0.070x | -10.30% |
| 2022-06-30 | €242.34 Million ≈ $283.32 Million |
€19.03 Million ≈ $22.25 Million |
0.079x | -65.25% |
| 2021-06-30 | €121.52 Million ≈ $142.07 Million |
€27.46 Million ≈ $32.11 Million |
0.226x | +379.96% |
| 2020-06-30 | €112.28 Million ≈ $131.27 Million |
€5.29 Million ≈ $6.18 Million |
0.047x | +682.01% |
| 2019-06-30 | €192.32 Million ≈ $224.84 Million |
€1.16 Million ≈ $1.35 Million |
0.006x | -86.45% |
| 2018-06-30 | €170.14 Million ≈ $198.91 Million |
€7.56 Million ≈ $8.84 Million |
0.044x | -69.36% |
| 2017-06-30 | €82.69 Million ≈ $96.67 Million |
€11.99 Million ≈ $14.02 Million |
0.145x | +35.98% |
| 2016-06-30 | €72.77 Million ≈ $85.08 Million |
€7.76 Million ≈ $9.07 Million |
0.107x | +171.00% |
| 2015-06-30 | €20.58 Million ≈ $24.06 Million |
€809.87K ≈ $946.83K |
0.039x | +134.35% |
| 2014-06-30 | €18.21 Million ≈ $21.29 Million |
€-2.09 Million ≈ $-2.44 Million |
-0.115x | -- |
About Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provi… Read more